Related Experiment Video
Updated: Sep 17, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Prevalence, practice pattern, and mortality of hyperkalemia in Chinese patients undergoing hemodialysis in the
Zhao Xinju1, Xing Changying2, Liu Hong3
1Department of Nephrology, Peking University People's Hospital, Unit 10C in Ward Building, 11 Xizhimennan Street, Xicheng District, Beijing, 100044, China.
Insights
Hyperkalemia (HK) affects 40.84% of Chinese hemodialysis (HD) patients, increasing mortality risks. Higher HK prevalence in HD centers correlates with greater patient deaths, indicating a need for better potassium management.
Area of Science:
- Nephrology
- Clinical Medicine
- Public Health
Background:
- Hyperkalemia (HK) is a common and serious complication in patients undergoing chronic hemodialysis (HD).
- Understanding the prevalence, risk factors, and impact of HK on mortality is crucial for improving patient outcomes in HD centers.
Purpose of the Study:
- To investigate the prevalence of HK and associated risk factors in Chinese patients on chronic HD.
- To examine the relationship between HK prevalence at the facility level and patient mortality.
- To assess the current management patterns of serum potassium (sK) and the utilization of potassium-binding drugs.
Main Methods:
- The Visualize-HD study enrolled 50,983 patients from 231 HD centers in China.
- Data collected included patient demographics, serum potassium levels, comorbidities, and mortality over three years.
- Statistical analyses were performed to identify risk factors for HK and associations with mortality at both patient and facility levels.
Main Results:
- The overall prevalence of HK (sK > 5.0 mmol/L) was 40.84%.
- Three-year cumulative mortality was 21.3%, with 36.7% of deceased patients having HK at their final test.
- Facilities with higher HK prevalence showed increased all-cause and cardiovascular mortality.
- Hyperphosphatemia and increased use of potassium-binding drugs were associated with higher facility HK prevalence.
Conclusions:
- Hyperkalemia is highly prevalent in Chinese HD centers and is linked to significant mortality risks.
- HD centers with higher HK prevalence experience greater patient mortality.
- Despite the importance of sK control, potassium-binding drugs appear to be underutilized, suggesting a need for improved management strategies.
Abstract:
Visualize-HD study aimed to examine prevalence of hyperkalemia (HK), associated practice patterns, and mortality in Chinese patients undergoing hemodialysis (HD). The study included patients aged ≥ 18 years and undergoing chronic HD for ≥ 3 months. Primary outcome was to examine the association between suspected risk factors and HK prevalence at the HD facility level. Secondary outcomes were to determine the HK prevalence, management pattern of serum potassium (sK), and risk factors associated with crude mortality. Overall, 50,983 patients undergoing HD from 231 HD centers were enrolled. HK prevalence (sK > 5.0 mmol/L) in patients undergoing HD was 40.84%. Proportion of patients sK > 5.5, > 6.0, > 6.5 mmol/L was 20.42%, 8.7%, and 3.21%, respectively. Three-year cumulative mortality of patients undergoing HD was 21.3%. Notably, 36.7% of deceased patients had HK as indicated by their final sK+ test results. Facilities in high HK prevalence group had a higher all-cause and cardiovascular mortalities compared with low HK prevalence group (20.7% vs. 21.9% and 11.5% vs. 13.5%; P < 0.05). A higher prevalence of hyperphosphatemia [hazard ratio (HR) 1.04 (95% confidence interval (CI): 1.01-1.07)] and more usage of potassium-binding drugs [HR 1.04 (95% CI: 1.00-1.07)] were positively associated with higher HK prevalence for facilities, whereas hypoalbuminemia prevalence and more elderly patients were reversely associated with higher HK prevalence for facilities. HK is prevalent in Chinese HD centers and is associated with risk factors. Chinese HD centers with a higher HK prevalence had higher mortality rates. Although, long-term sK control is important for improving survival in patients undergoing MHD, potassium-binding drugs are underused.Clinical trial registration number: NCT05020717.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Hemodialysis I: Introduction
Hemodialysis III: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care

